IO

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

Retrieved on: 
Monday, January 8, 2024
IO, ENT1, Survival, Place of birth, PD-1, Therapy, GSK, Lymphocyte, HNSCC, Patient, TIGIT, NSCLC, Equilibrative nucleoside transporter 1, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.

Key Points: 
  • and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.
  • “Over the past twelve months, the TIGIT competitive landscape has substantially evolved, further positioning iTeos and GSK as a potential leader with our high-quality TIGIT:PD-1 doublet, belrestotug + dostarlimab.
  • The Company plans to integrate IO-001 biomarker knowledge into the development strategy of future inupadenant clinical trials.
  • The Company continues to expect its cash balance to provide runway through 2026, which includes the initiation of multiple Phase 3 registrational trials assessing the belrestotug + dostarlimab doublet.

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

Retrieved on: 
Monday, January 8, 2024
IO, Protein engineering, Mural, Interleukin, Thought, Cancer, Patient, OS, PFS

DUBLIN, Ireland, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, announced strategic changes to its ARTISTRY-6 and ARTISTRY-7 clinical trials designed to generate more meaningful clinical data for these late-stage, potentially registrational trials of nemvaleukin.

Key Points: 
  • Mural plans to increase the size of this cohort by approximately 16 patients (to a total of approximately 90 patients) and expects a top-line data readout in the first half of 2025.
  • ARTISTRY-7 is a potentially registrational, phase 3 trial evaluating nemvaleukin as a monotherapy and in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
  • Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12, with plans to nominate development candidates for each program in 2024.
  • The Company’s cash resources of $275 million, as of November 15, 2023, are expected to fund its operations into 4Q 2025.

DreamBig World Leading "MARS" Open Chiplet Platform Enables Scaling of Next Generation Large Language Model (LLM), Generative AI, and Automotive Semiconductor Solutions

Retrieved on: 
Monday, January 8, 2024
Dai, IO, Architecture, Synthetic media, HBM, Bellini, RDMA, Engineering, LLM, AI, 3D, Chiplet, Generative, CPU, MARS, SVP, CES, HW, DRAM, SRAM, Data center, Video game

SAN JOSE, Calif., Jan. 8, 2024 /PRNewswire/ -- DreamBig Semiconductor, Inc. today unveiled "MARS", a world leading platform to enable a new generation of semiconductor solutions using open standard Chiplets for the mass market. This disruptive platform will democratize silicon by enabling startups or any size company to scale-up and scale-out LLM, Generative AI, Automotive, Datacenter, and Edge solutions with optimized performance and energy efficiency.

Key Points: 
  • DreamBig technology demonstration is showcased at CES 2024 in The Venetian Expo, Bellini 2003 Meeting Room
    SAN JOSE, Calif., Jan. 8, 2024 /PRNewswire/ -- DreamBig Semiconductor, Inc. today unveiled "MARS", a world leading platform to enable a new generation of semiconductor solutions using open standard Chiplets for the mass market.
  • This disruptive platform will democratize silicon by enabling startups or any size company to scale-up and scale-out LLM, Generative AI, Automotive, Datacenter, and Edge solutions with optimized performance and energy efficiency.
  • DreamBig "MARS" Chiplet Platform solves the two biggest technical challenges facing HW developers of AI servers and accelerators – scaling up compute and scaling out networking.
  • "The company has raised the technology bar to lead the semiconductor industry by delivering the next generation of open chiplet solutions such as Large Language Model (LLM), Generative AI, Datacenter, and Automotive solutions for the global mass market."

Logiwa Unveils The Next Generation in AI-driven Fulfillment Management Systems (FMS): Logiwa IO

Retrieved on: 
Thursday, January 4, 2024
Technology, Transport, Software, Logistics, Supply Chain Management, Retail, Data Management, Artificial Intelligence, Online Retail, IO, Architecture, Workforce, Learning, WMS, FMS, Automation, Inc., Warehouse

Logiwa Inc., a leading cloud based Fulfillment Management System (FMS) for high-volume fulfillment businesses, is excited to announce the launch of its innovative product update, Logiwa IO.

Key Points: 
  • Logiwa Inc., a leading cloud based Fulfillment Management System (FMS) for high-volume fulfillment businesses, is excited to announce the launch of its innovative product update, Logiwa IO.
  • Logiwa IO represents a pioneering shift in the world of fulfillment management, transcending traditional Warehouse Management Systems (WMS) limits.
  • Specially tailored for modern fulfillment challenges, Logiwa IO stands as a testament to Logiwa’s mission, "Fulfill Brilliantly."
  • “Logiwa IO is more than just an advancement in fulfillment technology; it's a transformative force reshaping the fulfillment landscape,” said Erhan Musaoglu, Founder & CEO of Logiwa.

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Retrieved on: 
Thursday, January 4, 2024
IO, Merck Group, ASX, Autoimmune disease, Immune system, Death, Bladder cancer, Carcinoma, Hope, IMM, PD-L1, Avelumab, Research, Cancer, Transitional cell carcinoma, Patient, Safety, Transitional epithelium

SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.

Key Points: 
  • The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.
  • Encouragingly, responses were achieved even in cancer patients with low and negative PD-L1 expression, who typically would not be expected to respond to anti-PD-(L)1 therapy.
  • Daniel Pink, as part of the investigator-initiated INSIGHT platform for studies investigating efti in different combination treatments and routes of administration.
  • For 2023, it was estimated there would be 82,290 new cases of bladder cancer and 16,710 deaths in the US alone.1

KBRA Releases Research – 5- and 10-Year Deal Credit Metrics

Retrieved on: 
Wednesday, January 3, 2024
Banking, Professional Services, Finance, IO, KLTV, CRE, KBRA, MSA, FY, Environment, CMBS, KDSC, Real estate

KBRA releases a report comparing the credit metrics between the 2023 5-year and 10-year conduit deals.

Key Points: 
  • KBRA releases a report comparing the credit metrics between the 2023 5-year and 10-year conduit deals.
  • This led to the market’s first CMBS conduit deal issuance that solely comprised 5-year loans.
  • Full-term interest-only (IO) loans were more concentrated in 5-year deals, representing 91.7% of the loans by balance, compared to 79.1% for 10-year deals.
  • For full-year (FY) 2023, 5-year deals averaged 29 loans, compared to 31 for 10-year deals.

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
IO, Biology, Research, Bristol Myers Squibb, Disease, Merck Serono, Therapy, Merkel-cell carcinoma, Cancer, Molecular biology, Master of Science, Novartis, M.A, Biochemistry, Proteomics, Neoplasm, Serono, Merck, Ipilimumab, AP3, Patient, ACRV, Medicine, Phase II, Pharmacology, Pharmaceutical industry

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.

Key Points: 
  • WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.
  • “Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “During his impressive career, he has effectively executed on advancing drugs from early development through regulatory approval, at both pharma and biotech companies.
  • Prior to Dragonfly, Dr. Cuillerot was the chief medical officer of Agenus, where he led development activities for five investigational therapies.

Himax and Seeed Studio Collaborate to Debut the Industry’s Most Innovative Battery-Powered Endpoint AI Vision Processing Module at CES 2024

Retrieved on: 
Tuesday, January 2, 2024
Cortex, Ethos, ECC, IO, PUF, GM, Interoperability, Software, DVFS, MIPI, Physical, AI, Internet of things, RSA, CES, Medical device

Positioned at the forefront of the industry, the processing module serves as a powerful endpoint AI development platform, paving the way for future AI applications.

Key Points: 
  • Positioned at the forefront of the industry, the processing module serves as a powerful endpoint AI development platform, paving the way for future AI applications.
  • These advantages make WE2 the ideal choice for the Seeed Studio Endpoint AI vision processing module.
  • The Seeed Studio Endpoint AI module, equipped with WE2, is a comprehensive development platform for endpoint AI devices that caters to diverse development needs for both software and hardware.
  • For software development, Seeed Studio’s Endpoint AI vision processing module not only provides dozens of pre-trained AI models but also features the EdgeLab AI toolchain.

IBN Upgrades Servers via Google Cloud and C3D Machines

Retrieved on: 
Tuesday, December 19, 2023
Cloud, C3D, IBN, IO, Google Cloud Platform, TB, Architecture, DDR5, Memory, Central processing unit, Video game

IBN will upgrade to Google’s new C3D Servers for no additional charge and with no downtime or client involvement.

Key Points: 
  • IBN will upgrade to Google’s new C3D Servers for no additional charge and with no downtime or client involvement.
  • The company is migrating from current servers to the new C3D machines because they are considerably more powerful and reliable and offer consistent performance and improved isolation and security.
  • IBN assessments demonstrated that the C3D machine's response time to be anywhere from 20-50 percent faster than the average response time of their current architecture.
  • Upgrading to the new C3D machines is another major advancement for IBN, for its proprietary platform solutions, and most importantly for its client partners.

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Retrieved on: 
Monday, December 11, 2023
IO, ESMO, Prognosis, Antibody, FDA, FTD, Melanoma, SAN, Congress, Novartis, Neoplasm, MEK, Oncology, NRAS, Patient, Safety, Journal, Binimetinib, Pharmaceutical industry

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm). Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.

Key Points: 
  • Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.
  • “The outcomes for patients with NRASm melanoma after frontline immunotherapy (IO) treatment are dismal with low response rates and short median progression free survival (mPFS).
  • Effective treatment options are needed for patients following progression on frontline IO with anti-CTLA-4 and/or anti-PD-(L)1 antibodies.
  • Erasca recently reported that End of Phase 2 meetings with the FDA and European health authorities confirmed the SEACRAFT-2 Phase 3 trial design and provided clarity on the registrational pathway.